Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Distribution deal a ‘major, major win’ for Akers Bio, says co-founder Ray Akers

Friday, December 2, 2016 3:02
% of readers think this story is Fact. Add your two cents.

Akers Biosciences Inc (LON:AKR, NASDAQ:AKER) is celebrating a milestone after the company trumpeted a major US distribution deal for its cholesterol self-testing kit.

The developer of rapid health information technologies has signed a distribution agreement with First Check Diagnostics, the major global diagnostic device and service provider.

Co-founder ray Akers tells Proactive: ”Even my bad cold today can’t dampen the excitement of this news. This is a major, major win for Akers Bio”

First Check will rebadge the Akers Tri-Cholesterol “Check” test and distribute it exclusively in the US under the “First Check” brand. The test does not require US Food & Drug Administration approval so it can be sold over the counter.

Akers adds: ”We’re happy to bring our shareholders good news and we know we have many, many more pieces of good news to follow.”

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.